Using Universal CART Immunotherapy for Aggressive T-Cell Cancers 

Summary

Relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are aggressive blood cancers. These cancers grow quickly and are hard to treat, especially when they come back or are resistant to therapy. Standard chemotherapy often stops working for aggressive T-cell cancer, and the cancers can spread to the brain or spinal cord, making treatment more complicated. There are also fewer targeted therapies for T-cell cancers compared to other types of leukemia or lymphoma. Although rare, T-cell cancers cause stress for families and require long and intense treatments. These treatments can be very expensive and difficult, placing a heavy burden on healthcare systems. 

Researchers at Washington University School of Medicine led a global study to test a new treatment for aggressive T-cell cancers. The treatment is called WU-CART-007. It is a type of immunotherapy using healthy donor cells that are edited in the lab with CRISPR technology. CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeat, is a tool that lets scientists precisely edit DNA, like using tiny scissors to fix or change genetic instructions. These cells can be prepared in advance and stored for future use. This capability allows for timely treatment and helps ensure consistency and quality control. It also reduces costs, provides logistical flexibility, and makes the treatment more scalable and accessible. 

The study tested WU-CART-007 on people with T-cell leukemia or lymphoma who did not respond to other treatments. For most people who received the recommended dose, the treatment caused their cancer to go into complete remission. This means that were no for patients in urgent need of care. WU-CART-007 reached clinical trials through a partnership with Wugen, a startup based in St. Louis. 

Significance

WU-CART-007 addresses a treatment gap for aggressive T-cell cancers. Current treatments are ineffective in about 60% of patients with aggressive T-cell cancers, and those patients often live for only 3 to 6 more months.¹ WU-CART-007 provides patients with the needed treatment quickly, while other typical treatments may take weeks or months to complete. This is because WU-CART-007 uses cells from a healthy donor whereas other therapies use the patient’s own cells. Scientists can store healthy donor cells in advance to potentially treat multiple patients. Other therapies using a patient’s own cells can take six to eight weeks because the cells must be modified after collection before injecting them back into the same patient.  

This feature supports health equity by offering effective care regardless of socioeconomic status. Developed at Washington University, WU-CART-007 catalyzed the growth of local company Wugen, supporting jobs and the biotech industry in St. Louis. WU-CART-007 also benefits the medical field by expanding access to advanced immunotherapy across geographically diverse clinical sites, offering rapid, off-the-shelf cell therapy that increases eligibility for curative stem cell transplantation. Curative stem cell transplantation replaces unhealthy cells with healthy ones to cure certain diseases, including cancers.

Additionally, Wugen has secured patents covering genome-edited CD7 CAR T technology. This treatment will inform regulatory guidance for the manufacture and clinical use of allogeneic CAR T cells, which is the use of T cells from healthy donors to create off-the-shelf treatment.

Benefits

Demonstrated benefits are those that have been observed and are verifiable.

Potential benefits are those logically expected with moderate to high confidence.

Clinical & medical benefits

Achieved complete remission in 8 of 11 evaluable trial participants (73 %).  demonstrated.

Therapeutic procedures

Reduced graft-versus-host risk by deleting (via CRISPR) native T-cell receptors in donor cells.  demonstrated.

Biological factors & products

Community & public health benefits

Provide rapid, off-the-shelf cell therapy that increases eligibility for curative stem cell transplantation.  potential.

Health care delivery

Expand access to advanced immunotherapy across geographically diverse clinical sites.  potential.

Health care accessibility

Improve quality of life and survival for people with aggressive blood cancers.  potential.

Life expectancy & quality of life

Economic benefits

Launched Wugen to translate university intellectual property, attracting significant venture investment and high-skill jobs.  potential.

Equitable healthcare economies (new TSBM benefit)

Secured patents covering genome-edited CD7 CART technology.  demonstrated.

Patents

Secured license agreements covering genome-edited CD7 CART technology.  demonstrated.

License agreements

Policy & legislative benefits

Inform regulatory guidance for allogeneic CAR T manufacture and clinical use.  potential.

Standards

This research has clinical, community, economic, and policy implications. The framework for these implications was derived from the Translational Science Benefits Model created by the Institute of Clinical & Translational Sciences at Washington University in St. Louis.²

Clinical

In this early trial, 28 patients in the U.S., Europe, and Australia received WU-CART-007. The treatment was given in different dose levels, and the best results came from the highest dose. Of the patients who received the highest dose, 91% saw improvements in their symptoms. Side effects were mostly mild to moderate.¹ 

The donor cells were edited to remove features that could cause them to attack the body or each other.^1,2 This editing made the cells more safe and effective. 

Community

Because WU-CART-007 can be frozen and shipped globally, patients can start treatment just 7 days after joining the study. This rapid turnaround is expected to widen access for rural and underserved populations once commercialized. The rapid access to WU-CART-007 will reduce the time patients have to wait for treatment to only a few days. In comparison, it can take 6 to 8 weeks to receive other cell therapy treatments. This shorter wait time could be the difference between living and dying. 

Economic

The technology behind WU WU-CART-007 helped launch Wugen in St. Louis. The company now supports manufacturing and clinical trials, and it is part of St. Louis’s growing biotech sector.^1,3   Also, since up to potentially 30 to 50 doses of WU-CART-007 can be generated from a single procedure removing healthy donor cells, the cost of care can be expected to be significantly less per patient. 

Policy

Early data from WU-CART-007 can inform FDA and international regulatory discussions on standards for universal donor cell products, including genome editing safeguards and potency assays. These rules could help future treatments reach patients faster. 

Lessons Learned

1. Cell therapies using healthy donor cells, or allogeneic CAR T-cell therapies, have not been approved by the FDA. This type of treatment is often rejected by the host’s immune system and may reduce the treatment’s persistence and efficacy. In the case of targeting CD7 or other T-cell targets, this may not be an issue because the cells that are targeted by WU-CART-007 are the same cells the are responsible for allogeneic CAR T-cell rejection. 
2. The ability to manufacture treatment efficiently is critical factor for success.
3. After WU-CART-007 therapy, patients may need a follow-up allogeneic stem cell transplant to maintain remission  
4. Patient resistance to WU-CART-007 or relapse following the treatment may result in the loss of CD7, which is a protein found on T cells. This requires further treatment as CD7 loss is associated with several types of cancers.